GVRP (GV Research Platform), a Hyderabad-based research organisation, has inaugurated the GVRP StepsBio Research Centre (GSRC), a strategic collaboration with Steps Biosciences that marks a significant milestone in India's pharmaceutical R&D landscape.

Located within the 1BLR life sciences cluster Lifescapes in Bengaluru, the 15,000 sq. ft. facility is a dedicated Centre of Excellence for formulations research and development. 

GSRC represents GVRP's strategic expansion into high-complexity formulations, an area that is becoming increasingly important in the global drug development pipeline.

The purpose-built facility integrates advanced scientific infrastructure and specialised workflows to support complex drug delivery systems, sterile injectables, and differentiated dosage forms. 

GSRC also complements GVRP's established preclinical capabilities, enabling an integrated development continuum from molecule discovery to formulated product development within a collaborative ecosystem.

Through GSRC, GVRP and Steps Biosciences aim to provide pharmaceutical and biotechnology companies with an advanced scientific environment to accelerate the development of next-generation therapies.

Kalyan Korisapati, Co-Founder, GVRP, said, "Through our collaboration with Steps Biosciences, we have created a facility that doesn't just meet today's R&D requirements, but is architected to scale alongside the evolving demands of global drug development.”

“GSRC strengthens our ability to offer partners a truly integrated scientific platform from preclinical research through to complex formulation development and we believe it positions India as a serious destination for high-value pharmaceutical innovation,” added Korisapati.

Manoj Nerurkar, Founder, Steps Biosciences, added, "At StepsBio, we are not only investing in physical infrastructure, but also in building AI-driven capabilities that will transform how we approach formulation design, predictive stability modelling, and process optimisation.”

“By integrating artificial intelligence into our scientific workflows at GSRC, we aim to dramatically reduce development timelines, improve decision-making at critical stages, and ultimately bring better therapies to patients faster,” added Nerukar.